This site and its domain are for sale. Email the owner if you want to talk about it.

bioclocktest.com

The TRIIM Trial and the Claim of Reversing Epigenetic Age

Nine volunteers got younger by a ruler that had not yet agreed with itself, and the follow-up trial is here to argue about it.

A wooden ruler lying across a row of small blood sample vials in a rack on a laboratory bench.

One thing that happens when someone invents a new kind of ruler is that the first person to measure something shrinking with it becomes famous, and everyone after that gets to argue about the ruler. The TRIIM trial is that first measurement for epigenetic age. It gave a small group of volunteers a year of recombinant human growth hormone (rhGH), dehydroepiandrosterone (DHEA) and metformin, read their blood with epigenetic clocks, and reported that their estimated biological ages went down.

The numbers: after 12 months, mean epigenetic age was about 1.5 years lower than at baseline, and the change in epigenetic age relative to chronological age was about minus 2.5 years compared to no treatment. On GrimAge, one of the four clocks used, the drop was about 2 years versus chronological age, and it was still there six months after treatment stopped. The paper, titled “Reversal of epigenetic aging and immunosenescent trends in humans,” called itself “the first report of an increase in predicted human lifespan via a currently accessible aging intervention, based on epigenetic age estimation.” It enrolled nine volunteers.

What the TRIIM trial measured, and when

The name stands for Thymus Regeneration, Immunorestoration, and Insulin Mitigation, which suggests the clocks were sort of a passenger and the immune system was driving. (The immune results are the other half of the paper’s title, and I am going to leave them to the paper.) The drug list is notable mostly for growth hormone, a substance with a long and colorful reputation in certain locker rooms, all of it presumably about thymus research.

The timing is the interesting part. From months 0 to 9, the reported rate of epigenetic aging was minus 1.6 years per year. From months 9 to 12 it accelerated to minus 6.5 years per year. So most of the action came late. Three months is three months.

Here is a hypothetical, invented and not a participant. A 60-year-old reverses at minus 6.5 years per year and never stops. Around age 69 his blood reads as a newborn’s. Around 70 it reads as someone who has not been born yet, which is a Benjamin Button plot the studio would have sent back as too much. Nobody claimed this, to be fair. But “predicted lifespan” is made of extrapolation (that is what the word predicted is doing), and the slope is the slope.

One more item belongs in the record, and it should be entered formally. Be it noted that at the commencement of the study, before any person received any drug, the participants’ epigenetic ages were, on average, lower than their chronological ages. That is to say: the instrument had already declared the volunteers younger than their birth certificates, prior to and independent of the intervention whose effect it was about to measure.

The obvious objection: it was nine people

The sensible reaction is that nine people is not a trial, it is a dinner party, or a book club or whatever. That reaction is correct. With nine people, one odd blood draw moves the average a lot. And with three drugs given together, there is no way to say which one did anything. The original study did not have control groups for either question (the follow-up’s registry listing is quite direct about this, in the polite way registries are direct).

To be fair, small first studies are how a lot of medicine starts: someone tries a thing on a handful of people, writes down what happened, and asks for money to try it on more. The problem is not that TRIIM was small. It is that its headline was not small.

But the point is that a small sample is the boring objection, because it is fixable. Run it with 900 people. The stranger problem survives that.

Why the comparison is stranger than the headcount

Look at the two headline numbers again. Mean epigenetic age fell about 1.5 years from baseline. The effect “compared to no treatment” was about 2.5 years. The gap between them is one year, which is also how long the study lasted. The arithmetic suggests that “no treatment” here means, in effect, the calendar: an untreated person is assumed to get one epigenetic year older per calendar year, and anything less counts as the drugs working. (I have checked my own calendar, and it is very consistent.)

Is that a crazy assumption? Not exactly. It is what the clocks were built to do on average. But it means the control arm, in a study without a control arm, is the clock’s promise to behave, and the thing being measured is whether the clock kept its promise. If the clock wanders on its own, the wandering shows up as effect.

I mean, picture the lab meeting. “Hey, good news, everyone got younger.” “Did we run them twice?” “Why would we run them twice?”

How much a clock wobbles on its own

Quite a lot, depending on whose numbers you use. For instance, one test company reports that technical replicates of published clocks (Horvath, Hannum, PhenoAge) produced deviations of three to nine years between measurements of the same sample. That is one company’s process, not the trial’s lab, and averaging across nine people narrows noise somewhat, so I don’t know how much of it applies here. The facts don’t settle it. But the reported effect was 2.5 years. The reported wobble goes to nine.

There is a second way to see the scale. The Horvath pan-tissue clock, which uses 353 CpG sites, has a mean absolute error of about 3.6 years when predicting chronological age across tissues, according to CD Genomics. So the clock’s ordinary miss on any one person is bigger than the trial’s average effect. That is not a contradiction (an average over nine people can be more precise than any single reading), but it gives a sense of how finely the instrument is being asked to cut. The Hannum clock, another one in the follow-up, uses 71 CpG sites and is built for blood.

There is also no shared yardstick. The Scientist reported that as of 2026 the field “has not yet achieved reference standards,” meaning you cannot send one sample to several validated labs and get the same age back. A 2026 systematic review of geroscience intervention trials found no comparative study where clock changes and changes in patient-important outcomes lined up uniformly. (The CALERIE calorie restriction trial, covered elsewhere on this site, found clock effects that were small.)

You and I both know what happens to a number like “minus 6.5 years per year” once it leaves a paper. It does not stay in the paper. I say this as someone whose job is mostly reading sentences containing the word “acceleration” and who still could not tell you his own GrimAge.

What TRIIM-X is supposed to fix

The follow-up is TRIIM-X, registered as NCT04375657. Intervene Immune’s program page says it uses multiple clocks including Horvath, Hannum, PhenoAge and GrimAge, and the registry listing says it includes control groups to test biomarker variability and the contribution of individual medications. That is, more or less exactly the two holes. A control group, for the record, is the part of a study that gets older on purpose.

Its stated objective is “to obtain information for designing an effective personalized and adaptive treatment regimen for a larger and more diverse study population.” Translated flatly: this study exists to help design the next study, which will have more people and let the recipe vary by person. It is an honest sentence, and also the most clinical-research sentence ever written, lol.

The facts here include no results from it yet. Whether the reversal holds up once there are controls is not settled. The measurement, meanwhile, comes with its own caveat in writing.

Elysium Health’s science page notes that a single epigenetic age sample processed repeatedly “can result in biological age estimates that vary up to nine years.”

Sources

  1. Reversal of epigenetic aging and immunosenescent trends in humans
  2. Our Programs - Intervene Immune
  3. The Science Behind Index | Elysium Health
  4. Four Aspects to Interpret Epigenetic Clock Results - CD Genomics
  5. Epigenetic Clocks Power Biological Age Data, But Why Do Results Differ Across Tests? | The Scientist
  6. Concordance between changes in epigenetic clocks and changes in clinical outcomes in geroscience intervention trials: A systematic review
  7. Thymus Regeneration, Immunorestoration, and Insulin Mitigation Extension Trial | Clinical Research Trial Listing ( Epigenetic Aging | Immunosenescence ) ( NCT04375657 )
  8. Effect of long-term caloric restriction on DNA methylation measures of biological aging in healthy adults from the CALERIE trial

Bio Clock Test explains published research. It is not medical advice and it does not diagnose anything. We never recommend a test, a supplement or a treatment. Talk to a clinician about your health.

Read next